Table 3.
Secondary outcomes*
| Outcome | Pre-SUPPORT N=1617 |
Post-SUPPORT N=2232 |
p Value† | Difference in means‡ (95% CI) |
Adjusted RR‡ (95% CI) |
Adjusted p value‡ |
|---|---|---|---|---|---|---|
| BPD or death at 36 weeks | 970/1617 (60.0) | 1199/2213 (54.2) | 0.0003 | – | 0.94 (0.89 to 0.99) | 0.03 |
| Severe ROP or death | 515/1581 (32.6) | 559/2165 (25.8) | <0.0001 | – | 0.85 (0.77 to 0.95) | 0.003 |
| Death before discharge | 358/1614 (22.2) | 393/2196 (17.9) | 0.001 | – | 0.93 (0.81 to 1.1) | 0.26 |
| BPD (36 weeks) | 664/1311 (50.7) | 855/1869 (45.8) | 0.0064 | – | 1.02 (0.95 to 1.1) | 0.55 |
| Severe ROP§ | 174/1294 (13.5) | 181/1875 (9.7) | 0.0009 | – | 0.66 (0.53 to 0.82) | 0.0002 |
| Death by 36 weeks | 306/1617 (18.9) | 344/2222 (15.5) | 0.0050 | – | 0.96 (0.83 to 1.1) | 0.59 |
| Death or mechanical ventilation on day 7 |
741/1613 (45.9) | 875/2211 (39.6) | <0.0001 | – | 0.90 (0.83 to 0.97) | 0.004 |
| Days on ventilator (survivors)¶ |
22.3 (24.4), 13 | 17.8 (21.3), 9.0 | <0.0001 | −4.2 (−5.7 to −2.7) | <0.0001 |
Presented as mean (SD), median for days on ventilator and n (%) for categorical variables.
Unadjusted p values from χ2 tests, or Wilcoxon tests, as appropriate.
Adjusted values (Post-SUPPORT vs Pre-SUPPORT) from robust Poisson models (categorical variables) or general linear models (continuous variables). All models include gestational age, birth weight (by 100 g increment), antenatal corticosteroids, gender, singleton versus multiple, race/ethnicity, caesarean section, rupture of membranes >24 h, maternal hypertension, maternal diabetes and NRN centre. The model for BPD also includes intubation in the DR, surfactant, FiO2 at 24 h, PDA ligation, PDA indometacin treatment and late onset sepsis.
For infants who had a ROP exam with complete information.
Survivors to discharge, transfer or 120 days, whichever came first, maximum is 120 days.
BPD, bronchopulmonary dysplasia; CI, confidence interval; DR, delivery room; FiO2, fractional inspired oxygen; NRN, Neonatal Research Network; PDA, patent ductus arteriosus; ROP, retinopathy of prematurity; RR, relative risk; SUPPORT, Surfactant, Positive Pressure, and Oxygenation Randomised Trial.